Showing 20 of 74 recruiting trials for “Cholangiocarcinoma”
Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
RecruitingNCT07101237 ↗
An Exploratory Study on Developing an Integrated Approach Combining Multimodal Imaging and Multi-omics Characterization of Tumor Heterogeneity for Precision Diagnosis and Treatment Optimization in Liver Cancer.
RecruitingNCT07291063 ↗
Anti-PD-1/PD-L1 Antibodies Plus Gemcitabine and Cisplatin for Advanced CCA
Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery
👨⚕️ Hop S Tran Cao, University of Texas MD Anderson Cancer Center LAO📍 58 sites📅 Started Jul 2024View details ↗
RecruitingNCT06505486 ↗
GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC
👨⚕️ Jia-yan Ni, M.D., Sun Yat-sem Memorial Hospital, Sun Yat-sen University📍 1 site📅 Started Jul 2024View details ↗
RecruitingNCT06643208 ↗
D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC
👨⚕️ Maolin Yan, Doctor, Department of Hepatobiliary Pancreatic Surgery, Fujian Provincial Hospital📍 1 site📅 Started Jul 2024View details ↗
The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer
Combined HAIC, Lenvatinib and Pucotenlimab As Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma
Robotically Assisted Surgery For Perihilar Cholangiocarcinoma: A Prospective Study
Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma
Evaluating a Community-Based Behaviour Change Communication Model to Prevent Cholangiocarcinoma in Khon Kaen, Thailand
Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)
Enrolling by InvitationNCT06474091 ↗
Liquid Biopsy MonitORing Of CholangioCarcinOma for Treatment Response and Prognostic Outcomes (MOROCCO)
Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy
Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma
Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC
RecruitingNCT06277531 ↗
Evaluation of diagnostiC Capacity of eccDNAs as Biomarkers in Indetermined biLiary Stricture(ECCBILE)
HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT)
RecruitingNCT06369480 ↗
Prognostic Factors for Survival in Patients With Cholangiocarcinoma
👨⚕️ Hans-Christian Pommergaard, M.D./Ph.D., Rigshospitalet, Denmark📍 1 site📅 Started Feb 2024View details ↗
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →